- Home
- BVC vs TRVI Comparison
BVC vs TRVI Comparison
Compare BVC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BVC | TRVI |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | Hong Kong | United States |
| Employees | 6 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BVC | TRVI |
|---|---|---|
| Price | $9.51 | $14.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $21.55 |
| AVG Volume (30 Days) | 1.6K | ★ 1.7M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.99 | $5.38 |
| 52 Week High | $15.00 | $16.12 |
Technical Indicators
Market Signals| Indicator | BVC | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 59.84 |
| Support Level | $9.20 | $10.07 |
| Resistance Level | $11.39 | $16.12 |
| Average True Range (ATR) | 0.60 | 0.76 |
| MACD | -0.22 | -0.05 |
| Stochastic Oscillator | 22.11 | 70.31 |
Price Performance
Historical ComparisonAbout BVC BitVentures Limited American Depositary Shares
BitVentures Ltd is a technology company focusing on exploring various opportunities in consumer technology, consumer healthcare and enterprise technology. The Company is developing technology businesses in verticals including e-commerce, digital assets, consumer healthcare, and other areas of consumer.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.